Preparation of kinase-biased compounds in the search for lead inhibitors of kinase targets

Medicinal Research Reviews

Volumn 25, Issue 3, 2005, Pages 310-330

  Lai, Justine Y Q ^a   Langston, Steven ^a,b   Adams, Ruth ^a   Beevers, Rebekah E ^a   Boyce, Richard ^a   Burckhardt, Svenja ^a   Cobb, James ^a   Ferguson, Yvonne ^a   Figueroa, Eva ^a   Grimster, Nett ^a   Henry, Andrew H ^a   Khan, Nawaz ^a   Jenkins, Kerry ^a   Jones, Mark W ^a   Judkins, Robert ^a   Major, Jeremy ^a   Masood, Abid ^a   Nally, James ^a   Payne, Helen ^a   Payne, Lloyd ^a   Raphy, Gilles ^a   Raynham, Tony ^a   Reader, John ^a   Reader, Valérie ^a   Reid, Alison ^a   Ruprah, Parminder ^a   Shaw, Michael ^a   Sore, Hannah ^a   Stirling, Matthew ^a   Talbot, Adam ^a   Taylor, Jess ^a   Thompson, Stephen ^a   Wada, Hiroki ^a   Walker, David ^a   more..

^a Millennium Pharmaceut R and D L   (United Kingdom)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

High throughput screening; Kinase inhibitors; Lead generation; Parallel synthesis

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; HYDROGEN; IMIDAZOLE DERIVATIVE; OLOMOUCINE; OXINDOLE; PHOSPHOTRANSFERASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PURINE DERIVATIVE; PURVALANOL A; PURVALANOL B; QUINAZOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; RPR 101511A; RPR 127963; SEMAXANIB; UNCLASSIFIED DRUG;

AUTOMATION; DRUG IDENTIFICATION; DRUG SYNTHESIS; EARLY DIAGNOSIS; ENZYME BINDING; ENZYME INHIBITION; ENZYME PURIFICATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; PHYSICAL CHEMISTRY; REVIEW;

DRUG DESIGN; IMIDAZOLES; INDOLES; ISOQUINOLINES; NAPHTHALENES; PROTEIN KINASE INHIBITORS; PURINES; PYRIMIDINES;

EID: 20144387361     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20026     Document Type: Review

References (59)

1. For a recent review on protein kinase inhibitors, see (a) Dumas J. Protein kinase inhibitors: Emerging pharmacophores 1997-2000. Expert Opin on Ther Patents 2001;11:405-429 and references cited therein.
2. Bridges AJ. Chemical inhibitors of protein kinases. Chem Rev 2001;101:2541-2571 and references cited therein.
3. Traxler P, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors Pharmacol Ther 1999;82:195-206.
4. Zaiac M. Taking aim at cancer. Chem in Britain 2002;38:44-46.
5. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J. Tyrosine kinase inhibitors: From rational design to clinical trials. Med Res Rev 2001;21:499-512.
6. O'Dwyer ME, Druker BJ. The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer. Current Cancer Drug Targets 2001;1:49-57.
7. de Bree F, Sorbera LA, Fernandez R, Castaner J. Imatinib mesilate. Treatment of chronic myeloid leukemia Bcr-Abl tyrosine kinase inhibitor. Drugs of the Future 2001;26:545-552.
8. Barker AJ, Gibson KH, Grundy W, Godfrey AA, Barlow JJ, Healy MP, Woodburn JR, Ashton SE, Curry BJ, Scarlett L, Henthorn L, Richards L. Studies leading to the identification of ZD1839 (Iressa): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911-1914.
9. Culy CR, Faulds D. Gefitinib. Drugs 2002;62:2237-2248.
10. Muhsin M, Graham J, Kirkpatrick P. Gefitinib. Nat Rev Drug Discov 2003;2:515-516.
11. Jamois EA, Hassan M, Waldman M. Evaluation of reagent-based and product-based strategies in the design of combinatorial library subsets. J Chem Inf Comput Sci 2000;40:63-70.
12. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25.
13. Clark DE, Pickett SD. Computational methods for the prediction of "drug-likeness". Drug Discovery Today 2000;5:49-58 and references cited therein.
14. For a more detailed introduction to the templates and their background as kinase inhibitors, see (a) García-Echeverría C, Traxler P, Evans DB. ATP site-directed competitive and irreversible inhibitors of protein kinases. Med Res Rev 2000;20:28-57 and references cited therein.
15. Stover DR, Lydon NB, Nunes JJ. Recent advances in protein kinases inhibition: Current molecular scaffolds used for inhibitor synthesis. Curr Opin Drug Discov Dev 1999;2:274-285 and references cited therein.
16. Myers MR, He W, Hulme C. Inhibitors of tyrosine kinases involved in inflammation and autoimmune disease. Curr Pharm Des 1997;3:473-502.
17. Traxler P. Tyrosine kinase inhibitors in cancer treatment (part II). Expert Opin Ther Patents 1998;8:1599-1625.
18. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW, Bridges AJ. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994;265(5175): 1093-1095.
19. Scrip 20030508T085009.
20. Wang YD, Miller K, Boschelli DH, Ye F, Wu B, Floyd MB, Powell DW, Wissner A, Weber JM, Boschelli F. Inhibitors of Src tyrosine kinase: The preparation and structure-activity relationship of 4-anilino-3-cyanoquinolines and 4-anilinoquinazolines. Bioorg Med Chem Lett 2000;10:2477-2480.
21. Boschelli DH, Wang YD, Ye F, Wu B, Zhang N, Dutia M, Powell DW, Wissner A, Arndt K, Weber JM, Boschelli F. Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles. J Med Chem 2001;44:822-833.
22. Berger D, Dutia M, Powell D, Wissner A, DeMorin F, Raifeld Y, Weber J, Boschelli F. Substituted-anilino-7-phenyl-3-quinolinecarbonitriles as Src kinase inhibitors. Bioorg Med Chem Lett 2002;12: 2989-2992.
23. Berger D, Dutia M, Powell D, Wu B, Wissner A, DeMorin F, Weber J, Boschelli F. 8-Anilinoimidazo[4,5-g]quinoline-7-carbonitriles as Src kinase inhibitors. Bioorg Med Chem Lett 2002;12:2761-2765.
24. Zhang N, Wu B, Powell DW, Wissner A, Floyd MB, Kovacs EID, Toral-Barza L, Kohler C. Synthesis and structure-activity relationships of 3-cyano-4-(phenoxyanilino)quinolines as MEK (MAPKK) inhibitors. Abstracts of Papers, 221st ACS National Meeting, 2001, MEDI-142.
25. Boyle FT, Gibson KH, Poyser JP, Turner P. Preparation of quinoline derivatives as inhibitors of MEK enzymes. PCT Int Appl 2000; WO 0068201.
26. For more information about the equipment, see www.hp-lab.de.
27. For more information about the equipment, see www.tecan.com.
28. Breault GA, Pease JE. Preparation of bis(arylamino)pyrimidine derivatives as anticancer agents. PCT Int Appl 2000; WO 0012485.
29. For more information about the equipment, see www.irori.com.
30. Farrant E, Rahman SS. A solid-phase synthetic route to substituted 7-azabenzimidazoles suitable for combinatorial library synthesis. Tetrahedron Lett 2000;41:5383-5386.
31. Zhu S, Shi S, Gerritz S, Sofia MJ. Attachment of unreactive amines to the solid support: Synthesis of phenyl-substituted anilines, 2-aminopyridines and 2-aminopyrimidines. J Combin Chem 2003;5:205-207.
32. Chang YT, Gray NS, Rosania GR, Sutherlin DP, Kwon S, Norman TC, Sarohia R, Leost M, Meijer L, Schultz PG. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem Biol 1999;6:361-375.
33. Nugiel DA, Cornelius LAM, Corbett JW. Facile preparation of 2,6-disubstituted purines using solid-phase chemistry. J Org Chem 1997;62:201-203.
34. For more information about the equipment, see www.advancedchemtech.com.
35. Adams JL, Lee D. Recent progress towards the identification of selective inhibitors of serine/threonine protein kinases. Curr Opin Drug Discov Dev 1999;2:96-109.
36. Lee HB, Balasubramanian S. Solid-phase synthesis of N-alkyl-N(b-keto) amides and 1,2,4,5-tetrasubstituted imidazoles using a traceless linker strategy. Org Lett 2000;2:323.
37. Lee A, Huang L, Ellman JA. General solid-phase method for the preparation of mechanism based cysteine protease inhibitors. J Am Chem Soc 1999;121:9907.
38. -1.
39. Purity based on analysis by ELLS.
40. Kajigaeshi S, Kakinami T, Moriwaki M, Fujisaki S, Maeno K, Okamoto T. Halogenation using quarternary ammonium polyhalides. Part X a-chlorination of aromatic acetyl derivatives with benzyltrimethylammonium dichloridate. Synthesis 1988;7:545.
41. -1).
42. Cobb JM, Grimster N, Khan N, Lai JYQ, Payne HJ, Payne LJ, Raynham T, Taylor J. Parallel synthesis of 1,2,4-trisubstituted imidazoles via N-alkyl-N-(β-keto)amides using a carbazate linker. Tetrahedron Lett 2002;43:7557-7560.
43. Buzetti F, Crugnola A, Ballinari D, Greco F. Preparation and formulation of azaindoles as tyrosine kinase inhibitors. PCT Int Appl 1994; WO 9414808.
44. Sugen subsequently discontinued the trials involving colorectal cancer patients due to a lack of clinical benefit. Press releases, Pharmacia, 16 Mar 2001 and 8 Feb 2002.
45. Sun L, Tran N, Liang C, Tang F, Rice A, Schreck R, Waltz K, Shawver LK, McMahon G, Tang C. Design, synthesis and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrolo-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases. J Med Chem 1999;42:5120-5130.
46. For more information about the equipment, see www.flexchem.net.
47. Reader VA, Boden CDJ, Cowell D, Grant CM, Jones M, Reader JC, Renou CC, Stirling M. Library synthesis using StAC technology: An efficient and inexpensive way of making compounds with 3 points of diversity or more on solid support. Abstracts of Papers, 222nd ACS National Meeting, 2001, ORGN-503.
48. Reader JC, Boden CDJ, Cowell D, Grant CM, Jones M, Reader VA, Renou CC, Stirling M. Multi-dimensional parallel solid-phase synthesis of libraries using StAC technology. Abstracts of Papers, 222nd ACS National Meeting, 2001, ORGN-589.
49. Reader JC. System and methods for the synthesis of spatially separated libraries of compounds. PCT Int Appl 2002; WO 0281077.
50. For more information about the equipment, see www.mimotopes.com.
51. Hidaka H, Inagaki M, Kawamoo S, Sasaki Y. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide-dependent protein kinase and protein kinase C. Biochemistry 1984;23:5036-5041.
52. Engh RA, Girod A, Kinzel V, Huber R, Bossemeyer D. Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89. Structural implications for selectivity. J Biol Chem 1996;21:26157-26164.
53. Lai Justine YQ, Ferguson Y, Jones M. Preparation of substituted quinolinyl and isoquinolinyl sulfonyl chlorides for the synthesis of novel sulfonamides. Synthetic Commun 2003;33:3427-3433.
54. -2mmol).
55. Kirschning A, Monenschein H, Wittenberg R. The "resin-capture- release hybrid technique: a merger between solid- and solution-phase synthesis. Chemistry - A European Journal 2000;6:4445-4450.
56. Solution-Phase Synthesis Technical Section. Resins and Reagents Catalog; Argonaut Technologies 2002; 104-105.
57. Jefferson EA, Sprankle KG, Swayze EE. Solid-phase synthesis of a heterocyclic ethylenediamine-derivatized library. J Combin Chem 2000;2:441-444.
58. Meurer LC, Tolman RL, Chapin EW, Saperstein R, Vicario PP, Zrada MM, MacCoss M. Synthesis and hypoglycemic activity of substituted 8-(1-piperazinyl)imidazo[1,2-a]pyrazines. J Med Chem 1992;35: 3845-3857 and references cited therein.
59. For more information about the equipment, see www.techne.com.